Cardiovascular defense challenges at the basic, clinical, and population levels

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 1-6

  Kovacic, Jason C ^a   Castellano, Jose M ^a   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Cardiovascular defense; Cardiovascular disease; Socioeconomic status

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TELOMERASE;

ABDOMINAL AORTA; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CELL AGING; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIFICATION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ECHOGRAPHY; EXERCISE; FEEDING BEHAVIOR; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; LIFESTYLE MODIFICATION; LOWEST INCOME GROUP; PATIENT IDENTIFICATION; POLYPHARMACY; PRIMARY PREVENTION; REVIEW; SMOKING CESSATION; TELOMERE SHORTENING; UNITED NATIONS;

EID: 84860469174     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06495.x     Document Type: Review

References (27)

1. Kovacic, J.C. et al 2011. From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. Clin. Pharmacol. Ther. 90: 509-518.
2. Kovacic, J.C. et al 2011. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation 123: 1650-1660.
3. Roger, V.L. et al 2012. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: e2-e220.
4. Moreno, P.R. et al 2009. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J. Am. Coll. Cardiol. 53: 2315-2323.
5. Rudd, J.H. et al 2010. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J. Am. Coll. Cardiol. 55: 2527-2535.
6. Underhill, H.R. et al 2010. MRI of carotid atherosclerosis: clinical implications and future directions. Nat. Rev. Cardiol. 7: 165-173.
7. Klink, A. et al 2011. Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nat. Rev. Cardiol. 8: 338-347.
8. Stone, G.W. et al 2011. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364: 226-235.
9. Kovacic, J.C. et al 2011. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation. 123: 1900-1910.
10. Campisi, J. et al 2007. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell. Biol. 8: 729-740.
11. Olive, M. et al 2010. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler. Thromb. Vasc. Biol. 30: 2301-2309.
12. Fayad, Z.A. et al 2011. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 378: 1547-1559.
13. Fayad, Z.A. et al 2011. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Am. Heart J. 162: 214-221 e2.
14. Navab, M. et al 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232.
15. Cannon, C.P. et al 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
16. Fayad, Z.A. et al 2011. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 378: 1547-1559.
17. Soe, K. et al 2011. Cardiovascular risk reduction via increasing HDL cholesterol: the promise of the dal-OUTCOMES Trial. Curr. Diab. Rep. 11: 4-6.
18. Muntendam, P. et al 2010. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am. Heart J. 160: 49-57 e1.
19. Boden, W.E. et al 2007. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356: 1503-1516.
20. Frye, R.L. et al 2009. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360: 2503-2515.
21. Epstein, R.S. 2011. Medication adherence: hope for improvement? Mayo Clin. Proc. 86: 268-270.
22. Muntner, P. et al 2011. Projected impact of polypill use among US adults: medication use, cardiovascular risk reduction, and side effects. Am. Heart J. 161: 719-725.
23. World Health Organization. 2009. World Health Statistics. Available at: Accessed 10 May 2011.
24. Fuster, V. et al 2011. Promoting global cardiovascular health: moving forward. Circulation 123: 1671-1678.
25. Kishore, S.P. et al 2011. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. J. Am. Coll. Cardiol. 57: 1980-1987.
26. Non-communicable diseases deemed development challenge of 'Epidemic Proportions'. Available at Accessed 16 Jan 2011.
27. Taylor, J. 2011. Science is the fundamental building block for every project in The Foundation for Science, Health, and Education (SHE). Eur. Heart J. 32: 662-663.